2025-06-04-Jefferies-科武斯（CRVS）_ITK抑制剂在高剂量数据更新中继续显示出对特应性皮炎的强效_11页_454kb

Corvus Pharmaceuticals: ITK Inhibitor SQL for Atopic Dermatitis Update

Company & Product

Corvus is a biopharmaceutical company developing clinical-stage oncology and immuno-oncology therapies, including an ITK inhibitor (SQL/CPI-818) for dermatological indications like Atopic Dermatitis (AD).

Key Updates

• Cohort 3 (n=12) of the Phase 1 AD study reported positive top-line data showing:
  • EASI-75 response: 50% (pbo-adjusted)
  • IGA 0/1 (clear or almost clear) response: 25%
• Data from the cohort at 200mg BID was in line with previously released Phase 1 (SID25) results and demonstrated better efficacy compared to relevant comparators (口服JAKi and Dupi).
• SQL achieved dose-dependent effects and earlier responses than seen in earlier cohorts.
• Safety profile remains favorable - no new safety signals, no dose-limiting toxicities.

Analyzed Data Points

• Expanded cohort includes patients with higher baseline EASI scores (27.2) vs lower scores in earlier cohorts.
• Reduction in mean EASI score: 64.8% vs 34.4% in placebo.
• Data surpasses JAKi and Dupi on key endpoints (EASI-75/IGA 0/1). SQL shows potential as a either novel, effective oral treatment for AD with a potentially bridging or combinatorial role alongside existing therapies.

Investment Thesis

• Upside Scenario: SQL becomes standard of care for PTCL, AD, and expands into broader oncology/solid tumors; Price Target USD 29.00 (+604%).
• Base Case Scenario: Continued positive AD Ph1 data plus oncology pipeline value; Price Target USD 13.00 (+216%).
• Downside: Failed trial or delayed commercialization; Price Target USD 0.01 (-100%).

Recommendation

• BUY rating with price target $13.00 (+216%) and upside potential, reflecting strong potential for oral AD treatment.

*注意: 以上总结基于提供的报告内容。请查阅完整报告以获取所有细节。*